Vyne Therapeutics Inc.

13F holders, Q2 2025 (June 30)
2holders +1
1new positions
0sold out
$1.65avg. 13F price*

At the end of Q2 2025, 2 institutions reported holding Vyne Therapeutics Inc. in their 13F filings, up 1 from Q1 2025. 1 opened new positions and 0 sold out. The largest holders were Staley Capital Advisers Inc. ($85K) and Farther Finance Advisors, LLC ($26).

Company
Vyne Therapeutics Inc.
CUSIP
92941V209
Latest filing quarter
Q2 2026

History

Number of 13F holders

0123 Q1 2024: 2Q1 2024Q2 2024: 2Q2 2024Q3 2024: 1Q3 2024Q4 2024: 1Q4 2024Q1 2025: 1Q1 2025Q2 2025: 2Q2 2025Q3 2025: 3Q3 2025Q4 2025: 2Q4 2025Q1 2026: 1Q1 2026Q2 2026: 1Q2 2026

Total Exit/New Position Q1 2025 → Q2 2025

InstitutionsTotal Value
New Positions1$26
Exits0$0

All 13F filers, Q1 2025 → Q2 2025: 16 shares bought, net +16 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 2 holders

Staley Capital Advisers Inc. 0.00% No change 51,472 $85K
Farther Finance Advisors, LLC 0.00% New 16 $26

"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.